Randomized trial shows finerenone reduces kidney function decline in adults with kidney disease — Evidence Review

A new randomized trial finds that finerenone slows kidney function decline and reduces major complications in adults with chronic kidney disease (CKD) without diabetes. These findings are consistent with prior research in diabetic CKD populations, suggesting that finerenone's benefits may extend to a broader patient group, as detailed by the study organization.

• Previous large-scale studies demonstrated that finerenone effectively slows disease progression and reduces cardiovascular events in patients with CKD and type 2 diabetes, indicating a similar mechanism of benefit in the non-diabetic CKD population 1 2 3.
• The new study expands upon this evidence, showing statistically and clinically meaningful improvements in eGFR decline and proteinuria among non-diabetic patients, aligning with established findings in diabetic cohorts 1 2.
• Related literature also highlights finerenone’s safety profile and favorable impact on heart failure and albuminuria outcomes, supporting its potential as a broadly applicable therapy for CKD, regardless of diabetes status 5 6 7.

Study Overview and Key Findings

Chronic kidney disease is a global health challenge, with limited treatment options for patients who do not have diabetes. This new international randomized trial addresses a crucial gap by evaluating whether finerenone, previously studied mainly in diabetes-related CKD, can slow the progression of kidney damage and reduce cardiovascular risks in non-diabetic CKD patients. The study is notable for its focus on a large, underserved population and its rigorous, multi-year design.

Property	Value
Study Year	2026
Organization	University Medical Center Groningen
Journal Name	New England Journal of Medicine
Authors	Hiddo J.L. Heerspink, Brendon L. Neuen, Rajiv Agarwal, David Z.I. Cherney, Carolyn S.P. Lam, Katherine R. Tuttle, Christoph Wanner, Pantelis Sarafidis, Niels Jongs, J. David Smeijer, Meike Brinker, Nicole Rethemeier, Patrick Schloemer, Paula Vesterinen, David Goldsbury, Sara Dizayee, Jon W. Mares, Vlado Perkovic
Population	Adults with chronic kidney disease without diabetes
Sample Size	n=1584
Methods	Randomized Controlled Trial (RCT)
Outcome	Kidney function decline, major kidney complications, cardiovascular events
Results	Finerenone reduced eGFR decline by 23% compared to placebo.

Literature Review: Related Studies

To evaluate how these findings fit within the broader scientific context, we searched the Consensus research database, which includes over 200 million papers. The following queries guided our search for relevant studies:

1. finerenone kidney disease outcomes
2. eGFR decline finerenone placebo comparison
3. kidney disease treatment new mechanisms

Topic	Key Findings
What is the efficacy of finerenone in slowing CKD progression and reducing cardiovascular events?	- Finerenone reduces the risk of kidney disease progression and cardiovascular events in patients with CKD and type 2 diabetes, as shown in multiple large RCTs 1 2 3. - Benefits include slower eGFR decline, reduced albuminuria, and fewer hospitalizations for heart failure 1 2 3 6.
How does finerenone perform in non-diabetic or broader CKD populations?	- Prior to the new study, most data on finerenone focused on diabetic CKD; this study is among the first to demonstrate its efficacy in non-diabetic CKD, filling a key research gap 1 2 3. - Finerenone's impact on kidney outcomes in broader or non-diabetic populations has been limited but shows promise 7.
What are the safety considerations and side effects of finerenone therapy?	- Finerenone generally has a favorable safety profile, with hyperkalemia-related treatment discontinuation occurring more frequently than placebo but remaining relatively low 1 2 3 5 7. - The risk of severe adverse events is comparable between finerenone and placebo groups in major trials 1 2 3 5.
What new mechanisms and therapeutic targets exist for CKD treatment?	- Research is increasingly focused on targeting inflammation, fibrosis, and novel pathways beyond blood pressure and glucose control to slow CKD progression 8 9 10 11 12. - Finerenone and other agents targeting mineralocorticoid receptors represent a new generation of therapies addressing these mechanisms 1 2 3 8 11.

What is the efficacy of finerenone in slowing CKD progression and reducing cardiovascular events?

The new trial's results are consistent with previous evidence from large randomized controlled trials in diabetic CKD populations, demonstrating that finerenone reduces both kidney and cardiovascular risks. The extension of these benefits to non-diabetic CKD patients supports finerenone’s potential as a broadly effective therapy.

• Multiple RCTs have shown finerenone slows eGFR decline and reduces albuminuria in CKD with type 2 diabetes 1 2 3.
• Cardiovascular benefits include reductions in heart failure hospitalizations and major adverse cardiovascular events 2 3 6.
• The magnitude of kidney function preservation in non-diabetic CKD appears similar to that in diabetic populations 1 2.
• The pooled FIDELITY analysis reinforces robust risk reductions for both kidney and cardiovascular outcomes 3.

How does finerenone perform in non-diabetic or broader CKD populations?

While most prior research focused on diabetic kidney disease, the new study is among the first to rigorously test finerenone in non-diabetic CKD. This addresses a major evidence gap and suggests potential benefit for a large, previously underserved group of patients.

• Earlier studies largely excluded non-diabetic CKD; this trial directly addresses that limitation 1 2 3.
• The FINEARTS-HF trial in heart failure patients (with and without diabetes) found reduced albuminuria but did not observe significant eGFR slope changes, possibly due to lower baseline kidney risk 7.
• The new evidence suggests that finerenone’s renoprotective and cardiovascular effects may extend beyond diabetic populations 1 2 7.
• Broader CKD research increasingly supports targeting inflammation and fibrosis, mechanisms addressed by finerenone 8 11.

What are the safety considerations and side effects of finerenone therapy?

Finerenone’s adverse event profile is generally favorable, with a modestly increased risk of hyperkalemia but similar rates of serious events compared to placebo. This safety profile has been consistent across diverse patient populations.

• Hyperkalemia-related discontinuation is more frequent with finerenone but remains uncommon 1 2 3 5 7.
• The overall rate of adverse events does not differ substantially from placebo, supporting its safety for long-term use 1 2 3 5.
• In non-diabetic CKD, as in diabetic populations, careful monitoring of potassium is necessary but the risk appears manageable 1 2 5 7.
• No new safety signals have emerged in recent studies, although ongoing surveillance is important 1 2 5 7.

What new mechanisms and therapeutic targets exist for CKD treatment?

Ongoing research emphasizes the need for new therapies targeting inflammation, fibrosis, and metabolic pathways in CKD. Finerenone’s mechanism—selective mineralocorticoid receptor antagonism—aligns with these emerging strategies.

• Traditional CKD treatments have focused on blood pressure and glucose control, but residual risk remains high 8 9 10 11.
• New approaches aim to modulate inflammation, fibrosis, and the gut microbiota to slow or prevent CKD progression 8 11 12.
• Finerenone represents a new class of agents acting on mineralocorticoid receptors, addressing pathophysiologic pathways involved in kidney injury and cardiovascular risk 1 2 3 8 11.
• Advances in basic science and biomarker discovery are guiding the development of further targeted therapies 8 10 11.

Future Research Questions

Although the new trial significantly advances knowledge about finerenone in non-diabetic CKD, further research is needed to clarify long-term outcomes, optimize patient selection, and explore additional mechanisms of benefit. The following questions highlight key areas for future investigation.

Research Question	Relevance
What are the long-term renal and cardiovascular outcomes of finerenone in non-diabetic CKD patients?	Long-term effects beyond 2–3 years remain unknown, and extended follow-up may reveal additional benefits or risks 1 2 3. Understanding durability and safety of finerenone in this population is crucial for clinical adoption.
How does finerenone compare to other emerging CKD therapies (such as SGLT2 inhibitors) in non-diabetic CKD?	Comparative effectiveness studies are needed to determine optimal therapy sequencing or combination, especially as new treatments like SGLT2 inhibitors are increasingly used in CKD care 8 12.
What are the predictors of response to finerenone in non-diabetic CKD?	Identifying patient characteristics, biomarkers, or genetic factors that predict greater benefit or risk can help tailor therapy and maximize effectiveness 8 10 11.
Does finerenone have differential effects across CKD etiologies in non-diabetic populations?	CKD is a heterogeneous condition; understanding whether finerenone benefits all non-diabetic CKD subgroups equally will inform clinical guidelines and personalized treatment 8 10 11.
What are the optimal strategies to monitor and mitigate hyperkalemia in patients receiving finerenone?	Hyperkalemia remains a concern; research on monitoring protocols and co-therapies could enhance safety and expand finerenone’s use in clinical practice 1 2 3 5 7.